Dolutegravir/rilpivirine
Combination of | |
---|---|
Dolutegravir | HIV integrase strand transfer inhibitor (INSTI) |
Rilpivirine | HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) |
Names | |
Trade names | Juluca |
Clinical data | |
Main uses | HIV/AIDS[1] |
Side effects | Diarrhea, nausea, headache[1] |
WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
Pregnancy category | |
Routes of use | By mouth |
External links | |
AHFS/Drugs.com | Monograph |
Legal | |
License data | |
Legal status |
Dolutegravir/rilpivirine, sold under the brand name Juluca, is a combination medication used to treat HIV/AIDS.[1] It is generally only used in people who have been stabilized on other treatments.[4] It may be the only medication a person requires.[1] It is taken by mouth daily with food.[1]
Common side effects include diarrhea, nausea, and headache.[1] Other side effects may include allergic reactions, liver problems, and depression.[1] Use in early pregnancy may harm the baby.[1] It contains dolutegravir, an integrase inhibitor, and rilpivirine, a reverse-transcriptase inhibitor.[1]
The combination was approved for medical use in the United States in 2017 and Europe in 2018.[1][5] In the United Kingdom a month of medication costs the NHS about £700 as of 2021.[6] This amount in the United States is about 2,900 USD.[7]
Medical uses
Dosage
It is taken at a dose of 50mg dolutegravir/25mg rilpivirine once per day.[6]
References
- 1 2 3 4 5 6 7 8 9 10 "Juluca- dolutegravir sodium and rilpivirine hydrochloride tablet, film coated". DailyMed. 24 October 2019. Archived from the original on 12 June 2020. Retrieved 25 March 2020.
- 1 2 "Dolutegravir / rilpivirine (Juluca) Use During Pregnancy". Drugs.com. 7 January 2020. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
- ↑ "Juluca 50 mg/25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 25 February 2020. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
- ↑ "Dolutegravir and Rilpivirine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 27 December 2021.
- ↑ "Juluca EPAR". European Medicines Agency (EMA). 11 February 2019. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
- 1 2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 681. ISBN 978-0857114105.
- ↑ "Juluca Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.
External links
Identifiers: |
---|
- "Dolutegravir mixture with rilpivirine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-03-26. Retrieved 2021-05-03.